Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review

Author:

Arlegui Hugo12,Nachbaur Gaëlle2,Praet Nicolas3,Bégaud Bernard1

Affiliation:

1. INSERM, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University of Bordeaux, Bordeaux, France

2. Pharmaco-Epidemiology and Health Outcomes Research, GSK, Rueil-Malmaison, France

3. Clinical Research and Development, GSK, Wavre, Belgium

Abstract

AbstractBackgroundAlthough rotavirus vaccines have proven to prevent the risk of rotavirus gastroenteritis (RVGE) in children under 5 years old, they are also associated with an increased transient risk of intussusception (IS). Several quantitative benefit-risk models (qBRm) are performed to measure this balance in hospitalizations and deaths prevented versus the ones induced.MethodIn this study, our objective was to provide a complete overview of qBRm used for rotavirus vaccination. We systematically searched 3 medical literature databases to identify relevant articles, in English, that were published between 2006 and 2019.ResultsOf the 276 publications screened, 14 studies using qBRm for rotavirus vaccination were retained, based on preselected criteria. Four were performed in low- and middle-income countries. Almost all (13 of 14) displayed the following characteristics: force of infection assumed to be constant over time (static model), indirect effect of rotavirus vaccination (herd effect) not considered, closed model (individuals not allowed to enter and/or exit the model over time), and aggregated level (no tracking of individual’s behavior). Most of the models were probabilistic (9 of 14) and reported sensitivity and/or scenario analyses (12 of 14). Input parameter values varied across studies. Selected studies suggest that, depending on the models used, for every IS hospitalization and death induced, vaccination would prevent, respectively, 190–1624 and 71–743 RVGE-related hospitalizations and deaths.ConclusionsThe benefits of rotavirus vaccination were shown to largely exceed the increased risk of IS, across all studies. Future research aiming to harmonize qBRm for rotavirus vaccination should ensure the comparability of studies and provide additional information for regulatory authorities, physicians, and patients.

Funder

GlaxoSmithKline Biologicals SA

Association Nationale pour la Recherche et la Technologie

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference58 articles.

1. Rotavirus vaccines. WHO position paper - January 2013;Wkly Epidemiol Rec,2013

2. Global review of rotavirus morbidity and mortality data by age and region;Sanderson,2011

3. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years;Troeger;JAMA Pediatr,2018

4. Withdrawal of rotavirus vaccine recommendation;Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,1999

5. Intussusception among infants given an oral rotavirus vaccine;Murphy;N Engl J Med,2001

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3